| Literature DB >> 34385841 |
Zhiming Zhao1, Huiwen Jin1, Yang Yin1, Yanwei Hou1, Jingyan Wang1, Chunling Tang2, Jun Fu1.
Abstract
PURPOSE: The relationship between food allergy caused by food specific IgG antibodies and migraine has received increased attention in recent years. Here, we aimed to evaluate the effects of food specific IgG antibodies on headache, gastrointestinal symptoms, anxiety, depression, sleep disorders, dermatosis, and serum inflammatory cytokines in migraine patients, and to quantitatively assess the effect of IgG levels on the severity of headache and its comorbidities.Entities:
Keywords: anxiety; food; gastrointestinal symptoms; immunoglobulin G antibody; interleukin-6; migraine; tumor necrosis factor- α
Year: 2021 PMID: 34385841 PMCID: PMC8352645 DOI: 10.2147/JPR.S316619
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1The frequency of the allergenic foods among 67 participants with positive IgG.
Comparison of the Participants’ Characteristics Between Different Food Specific IgG Groups
| Characteristicsa | IgG Negative | IgG Positive | |||||
|---|---|---|---|---|---|---|---|
| (n = 22) | Overall (n = 67) | With 1 Allergen (n = 36) | With 2 Allergens (n = 23) | With ≥3 Allergens (n = 8) | |||
| Age | 42.7 (10.4) | 39.6 (8.8) | 41.3 (9.6) | 38.3 (7.6) | 35.8 (6.8) | 0.19 | 0.21 |
| Gender (%Male) | 45.5% | 28.4% | 30.6% | 34.8% | 0 | 0.18 | 0.19 |
| BMI (kg/m2) | 22.7 (2.8) | 23.8 (3.9) | 24.1 (3.7) | 23.1 (3.9) | 24.6 (4.6) | 0.53 | 0.17 |
| With aura | 4.6% | 16.4% | 8.3% | 34.8% | 0 | 0.017 | 0.28 |
| Chronic migraine | 4.6% | 14.9% | 8.3% | 13.0% | 50% | 0.023 | 0.28 |
| Time elapsed since diagnosis (months) | 61.0 (44.1) | 107.8 (94.4) | 109.7 (113.5) | 107.8 (70.3) | 99.5 (63.6) | 0.96 | 0.0024 |
| MIDAS | 33.3 (15.6) | 50.5 (35.7) | 40.6 (23.1) | 57.1 (37.2) | 76.3 (59.9) | 0.019 | 0.0023 |
| Days with migraine in past 12 weeks | 15.5 (17.2) | 22.0 (19.4) | 17.1 (13.2) | 22.1 (16.7) | 44.0 (33.5) | 0.0011 | 0.14 |
| VAS | 6.5 (1.5) | 7.1 (1.3) | 6.9 (1.5) | 7.2 (1.2) | 7.5 (1.1) | 0.37 | 0.13 |
| HIT-6 | 57.9 (5.5) | 61.7 (6.1) | 59.9 (6.5) | 63.1 (4.5) | 65.8 (6.0) | 0.019 | 0.0095 |
| Days with migraine in past 4 weeks | 4.9 (5.3) | 7.5 (6.5) | 6.3 (4.9) | 6.9 (5.1) | 14.6 (11.5) | 0.0030 | 0.070 |
| MSQ | 25.2 (11.3) | 32.5 (12.8) | 28.6 (11.6) | 35.4 (12.8) | 41.4 (12.5) | 0.013 | 0.015 |
| GSRS | 26.9 (6.4) | 31.6 (11.0) | 28.3 (8.1) | 31.7 (8.9) | 45.9 (16.7) | <0.0001 | 0.018 |
| SDS | 40.1 (10.7) | 43.5 (11.0) | 42.6 (9.5) | 43.1 (10.7) | 48.8 (17.2) | 0.36 | 0.21 |
| Depression (%) | 18.2% | 28.4% | 22.2% | 30.4% | 50% | 0.25 | 0.41 |
| SAS | 38.8 (7.7) | 43.2 (10.5) | 42.0 (8.1) | 43.7 (9.3) | 47.5 (20.2) | 0.39 | 0.039 |
| Anxiety (%) | 13.6% | 23.9% | 16.7% | 34.8% | 25% | 0.33 | 0.38 |
| PSQI | 7.4 (3.5) | 8.0 (3.5) | 8.1 (3.0) | 7.7 (3.5) | 8.5 (5.3) | 0.84 | 0.50 |
| Poor sleeping (%) | 45.5% | 46.3% | 50% | 43.5% | 37.5% | 0.83 | 1.0 |
| Dermatosis (%) | 22.7% | 37.9% | 27.8% | 63.6% | 12.5% | 0.0081 | 0.30 |
| IL-6 (pg/mL) | 8.6 (3.8) | 12.6 (7.1) | 10.0 (5.1) | 13.8 (5.2) | 20.5 (11.9) | 0.0002 | 0.0013 |
| IL-10 (ng/L) | 173.2 (78.3) | 136.4 (96.0) | 159.7 (95.2) | 121.0 (99.8) | 75.9 (51.0) | 0.050 | 0.078 |
| TNF-α (pg/mL) | 12.0 (5.4) | 20.3 (12.1) | 15.3 (6.4) | 23.5 (11.7) | 33.5 (19.5) | <0.0001 | <0.0001 |
Notes: aNumeric data were described using mean (STD) and categorical data were described by proportion. bp values were obtained from ANOVA global test and Fisher’s exact test for the numeric and categorical data, respectively, for comparing the difference among three subgroups with different numbers of food specific allergens. cp values were from two independent t-tests and Fisher’s exact test for the continuous and categorical data, respectively, for comparing the difference between the IgG positive group vs IgG negative group.
Abbreviations: BMI, body mass index; MIDAS, Migraine Disability Assessment questionnaire; VAS, Visual Analog Scale; HIT-6, Headache Impact Test-6; MSQ, Migraine-Specific Quality of Life Questionnaire; GSRS, Gastrointestinal Symptom Rating Scale; SDS, Self-Rating Depression Scale; SAS, Self-Rating Anxiety Scale; PSQI, Pittsburgh Sleep Quality Index; IL-6, interleukin-6; IL-10, interleukin-10; TNF-α, tumor necrosis factor-α.
The Association Between Migraine and Comorbidities and the Overall Positive IgG Concentration Before and After Adjusting for the Inflammatory Cytokines
| Migraine and Comorbidities | Coefficient (95% CI)a | |||
|---|---|---|---|---|
| Not Adjusting for IL-6, IL-10, and TNF-α | Adjusting for IL-6, IL-10, and TNF-α | |||
| Time elapsed since diagnosis (months) | 0.58 (−0.94, 2.09) | 0.45 | 0.36 (−2.26, 2.99) | 0.78 |
| MIDAS | 1.31 (0.84, 1.78) | <0.0001 | 0.63(−0.17, 1.42) | 0.12 |
| Days with migraine in past 12 weeks | 0.70 (0.44, 0.96) | <0.0001 | 0.53 (0.14, 0.91) | 0.0083 |
| VAS | 0.002 (−0.019,0.023) | 0.85 | 0.011 (−0.026, 0.048) | 0.55 |
| HIT-6 | 0.084 (−0.011, 0.18) | 0.083 | 0.0049 (−0.16, 0.17) | 0.95 |
| Days with migraine in past 4 weeks | 0.19 (0.099, 0.29) | 0.0001 | 0.15 (0.0074, 0.29) | 0.04 |
| MSQ | 0.18 (−0.020, 0.38) | 0.077 | −0.022 (−0.36, 0.31) | 0.89 |
| GSRS | 0.31 (0.16, 0.47) | 0.0002 | 0.36 (0.11, 0.62) | 0.0053 |
| SDS | 0.17 (−0.00061, 0.34) | 0.051 | 0.16 (−0.13, 0.44) | 0.27 |
| SAS | 0.14 (−0.024, 0.31) | 0.093 | 0.13 (−0.12, 0.38) | 0.32 |
| PSQI | −0.0084 (−0.064, 0.047) | 0.76 | 0.01 (−0.084, 0.10) | 0.83 |
| OR (95% CI)a | ||||
| With aura | 1.003 (0.96, 1.05) | 0.91 | 1.00 (0.93, 1.07) | 0.97 |
| Chronic migraine | 1.08 (1.03, 1.13) | 0.0015 | 1.07 (0.99, 1.16) | 0.099 |
| Depression | 1.03 (0.99, 1.06) | 0.11 | 0.99 (0.93, 1.06) | 0.75 |
| Anxiety | 1.01 (0.98, 1.05) | 0.48 | 0.98 (0.91, 1.06) | 0.59 |
| Poor sleeping | 0.98 (0.95, 1.01) | 0.22 | 1.01 (0.95, 1.07) | 0.84 |
| Dermatosis | 1.01 (0.98, 1.05) | 0.42 | 0.99 (0.94, 1.05) | 0.75 |
Note: aAssociations were all reported as every 10 u/mL increase in the overall positive IgG level.
Abbreviations: MIDAS, Migraine Disability Assessment questionnaire; VAS, Visual Analog Scale; HIT-6, Headache Impact Test-6; MSQ, Migraine-Specific Quality of Life Questionnaire; GSRS, Gastrointestinal Symptom Rating Scale; SDS, Self-Rating Depression Scale; SAS, Self-Rating Anxiety Scale; PSQI, Pittsburgh Sleep Quality Index; IL-6, interleukin-6; IL-10, interleukin-10; TNF-α, tumor necrosis factor-α.